Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-09-08

Clinical Trial Update: Safety and Tolerability of Rapid Dose Titration of Subcutaneous Remodulin® Therapy in PAH Subjects (RAPID) [Phase 4]

View source ↗

Summary

Phase 4 safety and tolerability study evaluating rapid dose titration of subcutaneous Remodulin in patients with pulmonary arterial hypertension. Results have b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Remodulin (treprostinil)

Snippet

Sponsor: United Therapeutics | Conditions: Pulmonary Arterial Hypertension | Phase 4 | Status: COMPLETED | Results posted: 2017-09-08